OREANDA-NEWS. December 21, 2012. OJSC Pharmacy Chain 36.6 [RTS: APTK; MICEX: RU14APTK1007] - the leading Russian pharmaceutical retailer announces 9M 2012 financial results prepared in accordance with the International Financial Reporting Standards (unaudited).

SALES:

Consolidated sales from ongoing operations in 9M 2012 reached RUR 15 588 mln which is a decrease of 1%;

Net sales in the retail pharmacy segment in 3Q 2012 increased by 6% and reached RUR 3 492 mln. In 9M 2012 retail sales reached RUR 10 939mln which is an increase of 3% compared to sales in 9M 2011.

As of the end of 9M 2012 Pharmacy Chain 36.6 operated 892 pharmacies, 9 stand-alone optical outlets and 24 additional optical departments within pharmacies.

PROFIT:

Consolidated gross profit in 9M 2012 reached RUR 6 290 mln, which is a decrease of 8%;

Gross profit of the retail pharmacy segment in 9M 2012 reached RUR 3 153 mln, which is a decrease of 9%. The gross profit margin in the retail segment in 9M 2012 decreased as a percentage of sales by 4 points to 29%;

The Company’s consolidated EBITDA reached RUR 1 189 mln, which is a decrease of 9%; Company’s consolidated EBITDA margin decreased by 4 point;

EBITDA loss in the retail pharmacy segment in 9M 2012 reached RUR 171 mln versus profit of RUR 40mln in 9 2011;

Consolidated selling, general and administrative expenses decreased in 9M 2012 by 2% and reached RUR 5 574 mln;

SG&A of the retail pharmacy segment in 9M 2012 increased by 0.5% and reached RUR 3 686 mln.

Consolidated Net loss in 9M 2012 reached RUR 650mln versus RUR 552 mln in 9M 2011.

FINANCIAL DEBT AND INVESTMENTS

Company’s Net Debt (deducting the remaining monetary funds) equaled to RUR 8 557 mln;

As of the end of 9M 2012 consolidated financial debt reached RUR 10 268 mln which is an increase of 7% versus the beginning of the year data. Whereas the retail pharmacy financial debt equaled to RUR 8 689 mln and Veropharm’s debt reached RUR 1 579 mln;

Consolidated finance costs in 9M 2012 increased by 7% and reached RUR 1 144 mln;

Consolidated investments in fixed and intangible assets in 9M 2012 reached RUR 723 mln, out of which retail investments in opening new pharmacies and re-branding equaled to RUR 80 mln, Veropharm investments reached RUR 643 mln.

VEROPHARM

For the latest update on 9M 2012 performance please refer to the official press-release of the company as of November 30th, 2012 at www.pahrmacychain366.ru.

ELC

At July 26, 2012 Group sold its share of 50% in the ‘Early Learning Center’ at a price of RUR 242 mln. Early Learning Center revenue consolidated by the Group (which is 50% of the total revenue) equaled to RUR 119 mln, net loss equaled to RUR 1,72 mln, as of the moment of disposal, the unit operated 19 stores.